

Draft Resolutions of the Ordinary General Meeting of Shareholders

The Ordinary General Meeting of Shareholders of Antibiotice S.A., a trading company established and operating according to the Romanian law, registered at the Trade Register Office Iasi attached to the Court of Iasi, under the no. **J1991000285223**, unique registration code RO1973096, headquartered in 1 Valea Lupului St., Iasi, Romania, having subscribed and paid-up capital in the amount of 67,133,804 LEI divided in 671,338,040 ordinary registered shares, with a nominal value of 0.10 lei each,

convened by the announcement published in the Official Gazette of Romania, Part IV, no. 3443/25.07.2025 and in Evenimentul no. 10447 dated on 25.07.2025, (and republished in the Official Gazette of Romania, Part IV, no. .../... and in Evenimentul no. dated on)

according to the provisions of Law no. 31/1990 on trading companies, republished, with the subsequent amendments and completions, Law no. 24/2017 on issuers of financial instruments and market operations, republished, FSA Regulation no. 5/2018 on issuers of financial instruments and market operations, with the subsequent amendments and completions, Government Emergency Ordinance no. 109/2011 on corporate governance of public enterprises and provisions of the company's Articles of Association,

reunited on 26/27.08.2025 at 10 AM for an Ordinary Meeting at Antibiotice headquarters, for the first reunion/second reunion, gathering shareholders representing% of the share capital, respectively% of the total no. of voting rights, statutory and legally constituted,

following the debates,

DECIDES:

Resolution no.1: With the "for"/"against" votes of the shareholders representing ...% of the total votes cast, the Ordinary General Meeting of Shareholders approves/does not approve the project entitled "Research and Development Center Inova a+ and critical medicines production" which will be submitted for funding under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)", Priority 9, "Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector" and the related expenses in value of 376,877,912.87 lei, VAT-free. Antibiotice S.A. undertakes to ensure that it has the financial capacity to provide its own contribution to both the eligible and non-eligible project expenditures, under the conditions of subsequent reimbursement/settlement of the expenses. Antibiotice S.A. undertakes, for a 5-year period from the date of completion of the investment, in accordance with the state aid scheme and the provisions of Article 65 of Regulation (EU) No. 2021/1060, to maintain the investment made

by covering the related operating and maintenance costs, as well as the necessary associated services, in order to ensure its financial sustainability.

Resolution no.2: With the "for"/"against" votes of the shareholders representing ...% of the total votes cast, the Ordinary General Meeting of Shareholders approves/does not approve technical and economic indicators of the project entitled "Research and Development Center Inova a+ and critical medicines production", which will be submitted for financing under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, conducted by Health Program Managing Authority", Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector".

Resolution no.3: With the "for"/"against" votes of the shareholders representing ...% of the total votes cast, the Ordinary General Meeting of Shareholders approves/does not approve the authorization of the Management Board to issue resolutions approving, based on supporting documentation, the exact amount of expenses related to the project "Research and Development Center Inova a+ and critical medicines production" and its technical-economic indicators which will be submitted for funding under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)", Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector, provided they are kept within the maximum value of 376,877,912.87 lei, VAT-free.

These decisions shall be signed today 26/27.08.2025 at the company's headquarters, in two original copies.

President of the Management Board,
Ionut-Sebastian IAVOR